Browse tables and figures, 05 company profiles spread across 102 pages at http://www.reportsnreports.com/reports/998417-global-botulinum-market-research-report-2017.html .
Global Botulinum Market Report 2017 is a professional and in-depth survey on the current state of the Botulinum industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status.
Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Botulinum in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Botulinum in each application.
This report studies Botulinum in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering XOMA Corporation, AlphaVax Microbiotix, Molecular Targeting Technologies and Morphotek. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=998417 .
The 'Global and Chinese Botulinum Toxins Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Botulinum Toxins industry with a focus on the Chinese market. The report provides key statistics on the market status of the Botulinum Toxins manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Botulinum Toxins industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis
The Global Botulinum Toxins Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Botulinum Toxins industry.
Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum Toxins market analysis is provided for the Global market including development history, competitive landscape analysis, and major regions' development status.
Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin.
This report studies Botulinum Neurotoxins in Global market, focuses on price, sales, revenue of each type in Global. This report also focuses on the sales (consumption), production, import and export of Botulinum Neurotoxins in global market, forecast to 2021, from 2016. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Botulinum Neurotoxins, revenue and market share, for key manufacturers.
The Botulinum Neurotoxins industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.

Browse tables and figures, 05 company profiles spread across 102 pages at http://www.reportsnreports.com/reports/998417-global-botulinum-market-research-report-2017.html .
Global Botulinum Market Report 2017 is a professional and in-depth survey on the current state of the Botulinum industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum market analysis is provided for the international market including development history, competitive landscape analysis, and major regions' development status.
Market Segment by Regions, this report splits Global into several key Region, with production, consumption, revenue, market share and growth rate of Botulinum in these regions, from 2012 to 2022 (forecast), like North America, China, Europe, Japan, India, Southeast Asia split by product type, with production, revenue, price, market share and growth rate of each type Split by application, this report focuses on consumption, market share and growth rate of Botulinum in each application.
This report studies Botulinum in global market, focuses on top manufacturers in global market, with sales, price, revenue and market share for each manufacturer, covering XOMA Corporation, AlphaVax Microbiotix, Molecular Targeting Technologies and Morphotek. Order a copy at http://www.reportsnreports.com/purchase.aspx?name=998417 .
The 'Global and Chinese Botulinum Toxins Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Botulinum Toxins industry with a focus on the Chinese market. The report provides key statistics on the market status of the Botulinum Toxins manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2012-2017 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Botulinum Toxins industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis
The Global Botulinum Toxins Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Botulinum Toxins industry.
Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Botulinum Toxins market analysis is provided for the Global market including development history, competitive landscape analysis, and major regions' development status.
Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin.
This report studies Botulinum Neurotoxins in Global market, focuses on price, sales, revenue of each type in Global. This report also focuses on the sales (consumption), production, import and export of Botulinum Neurotoxins in global market, forecast to 2021, from 2016. Firstly, this report focuses on price, sales, revenue and growth rate of each type, as well as the types and each type price of key manufacturers, through interviewing key manufacturers. Second on basis of segments by manufacturers, this report focuses on the sales, price of each type, average price of Botulinum Neurotoxins, revenue and market share, for key manufacturers.
The Botulinum Neurotoxins industry development trends and marketing channels are also analyzed and the feasibility of new investment projects are assessed and overall research conclusions offered. With the tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.

ADCC is a function used by several commercial and experimental-stage therapeutic antibodies to target the host's immune system to destroy tumor cells that are bound by the antibody2. Farletuzumab has been shown in previous in vivo preclinical studies to utilize immune-effector activities including ADCC and complement mediated cytotoxicity (CDC) to kill target cells, as well as induce an intracellular death program called autophagy3-5. While the relationship of these pathways on optimal tumor cell killing is still being studied, evidence has shown that removal of at least one of these components results in significantly diminished farletuzumab anti-tumor activity3,4. These data now support the scientific relationship between CA125 levels and potential clinical outcomes of patients when treated with farletuzumab. To address this hypothesis, the effects of CA125 on farletuzumab pharmacologic activity when combined with standard of care chemotherapy are being further investigated in a clinical trial currently recruiting patients with low serum CA125 (NCT02289950).
About Morphotek
Morphotek®, Inc., a subsidiary of Eisai Inc., is a clinical-stage biotechnology company focused on developing novel classes of biological-based products to treat cancer, inflammatory and infectious diseases. Our mission is to develop novel, targeted therapies that attack underlying disease pathways and overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies. Our diverse pipeline includes clinical-stage monoclonal antibodies to lead targets folate receptor alpha, mesothelin and endosialin, as well as antibody drug conjugates and bispecific antibodies to undisclosed targets in preclinical development. Our mission is supported by the proprietary cutting-edge technologies in antibody engineering, manufacturing and screening optimization platforms, along with our expertise in developing diagnostics to support patient selection and therapeutic strategy. For more information, please visit www.morphotek.com.
About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

MarketStudyReport.com adds “Global Gout Therapeutics Market 2016-2020” new report to its research database. The report spread across 59 pages with table and figures in it.
The research analysts forecast the global gout therapeutics market to grow at a CAGR of 17.16% during the period 2016-2020.
About Gout Therapeutics
Gout is one type of arthritis, which is caused by the high levels of uric acid in the blood. The main symptoms of gout are sudden attack of burning pain, swelling in a joint, and stiffness, usually in toe. If it is not treated, over time, it can harm tendons, joints, and other tissues. NSAIDs and urate-lowering agents are preferred treatment options for gout.
Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-gout-therapeutics-market-2016-2020/
Covered in this report
The report covers the present scenario and the growth prospects of the global gout therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of gout and the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Research report, Global Gout Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
AstraZeneca
Horizon Pharma
Takeda Pharmaceuticals
Other prominent vendors
Ablynx
Alder Biopharmaceuticals
Antares Pharma
Astellas Pharma
Boehringer Ingelheim
Can-Fite BioPharma
Celgene
Celltrion
ChemoCentryx
CymaBay Therapeutics
Eisai
Eli Lilly
Gilead Sciences
GlaxoSmithKline
Incyte
Ironwood Pharmaceuticals
JW Pharmaceutical
KaloBios Pharmaceuticals
Lexicon Pharmaceuticals
LG Life Sciences
Merck
Morphotek
Novartis
Novo Nordisk
Regeneron Pharmaceuticals
Sandoz
Sanofi
Santarus
Selecta Biosciences
Teijin Pharma
UCB
Vertex Pharmaceuticals.
Market driver
Introduction of novel urate-lowering agents
For a full, detailed list, view our report
Market challenge
Low physician and patient awareness
For a full, detailed list, view our report
Market trend
Focus on regenerative medicines
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150

WiseGuyReports.Com Publish a New Market Research Report On – “Immunotherapy Drugs Market Global Potential Growth,Share,Demand and Analysis Of Key Players Research Report Forecasts to 2020”.
This market research report presents a comprehensive segmentation of the global immunotherapy drugs market by type of immunotherapy (mAbs, vaccines, immune checkpoint inhibitors, non-specific immunotherapies, and others), by therapy area (oncology, infectious disease, autoimmune and inflammatory disorders, respiratory diseases, and others), and by geography (the Americas, APAC, and EMEA). Key vendors are AbbVie, Amgen, Bristol-Myers Squibb, F.Hoffmann-La Roche, Johnson & Johnson, and Merck.
Overview of the global immunotherapy drugs market
The market research analyst predicts that the global immunotherapy drugs market will grow at a steady CAGR of close to 12% by 2020. During a rise in cancer and a number of autoimmune diseases, the need for immunotherapy drugs is on the rise. Furthermore, with the increasing demand for mAbs, the market for immunotherapy drugs will have a positive outlook until the end of the forecast period. mAbs have a high affinity for specific disease cells and areas that need treatment. Consequently, they can be used for therapies like radioimmunotherapy and antibody-directed enzyme prodrug therapy. The augmented usage of these antibodies in drug development will help to bolster the market’s revenue generating capacity over the course of the next four years.
For more information or any query mail at [email protected]
An important factor impelling the prospects for growth in this market is the emergence of biosimilars. Unlike generic drugs, which have active pharmaceutical ingredients similar to original drugs, biosimilars are almost identical to their originator biologic compounds. Since biosimilars help to make treatments more accessible to patients and are less expensive than biologics, their sale among the end users is anticipated to increase significantly over the next few years.
Segmentation by type of immunotherapy and analysis of the immunotherapy drugs market
- mAbs
- Vaccines
- Immune checkpoint inhibitors
- Non-specific immunotherapies
During 2015, the mAbs segment dominated this market and accounted for an impressive market share of nearly 61%. The development of new drugs and the entry of new molecules like zanolimumab, elotuzumab, obinutuzumab, and onartuzumab into the market will aid in the growth of this market segment during the forecast period.
Geographical segmentation and analysis of the immunotherapy drugs market
- Americas
- APAC
- EMEA
The Americas dominated the global market with over 50% market share in 2015. The market is flourishing in this region due to the higher incidences of cancer, infectious diseases, and autoimmune diseases in the US. Additionally, factors such as the high affordability of therapies due to the presence of well-structured reimbursement plans will also spur the prospects for market growth until 2020.
Competitive landscape and key vendors
The global market for immunotherapy drugs is highly competitive due to the presence of a number of large and small vendors. Many of these vendors have a huge global presence and enter into strategic alliances to aid in the manufacture and marketing of essential drugs. Safety and effectiveness of drugs are key factors, which will give vendors an edge in the marketplace.
Key vendors in this market are -
AbbVie
Amgen
Bristol-Myers Squibb
F.Hoffmann-La Roche
Johnson & Johnson
Merck
Other prominent vendors are AB Science. Ablynx, Acorda Therapeutics, ADC Therapeutics, Aduro Biotech, Advantagene, Advaxis, Agensys, Agenus, Alder Biopharmaceuticals, AlphaVax, Altor BioScience, Antares Pharma, Antigen Express, Argos Therapeutics, Astellas Pharma, AstraZeneca, AVAX Technologies, Bavarian Nordic, Baxter, Bayer, Biogen, Biotech Pharmaceutical, Biothera, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celldex Therapeutics, Celltrion, Cel-Sci, ChemoCentryx, Chugai Pharmaceutical, Coherus BioSciences, CTI BioPharma, CureVac, Daiichi Sankyo, Eisai, Eli Lilly, Fortress Biotech, Galena Biopharma, Genexine, Genmab, Gilead Sciences, GSK, GlobeImmune, Gradalis, Heat Biologics, Hospira, Idera, Inmatics, ImmunoCellular Therapeutics, Immunomedics, ImmuPharma, Immutep, Incyte, Inovio Pharmaceuticals, Intas Pharmaceuticals, Invion, ISA Pharmaceuticals, Janssen Biotech, Juvaris Biotherapeutics, KaloBios Pharmaceuticals, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, MedImmune, Morphotek, Neovii Biotech, Northwest Biotherapeutics, Novartis, NovaRx, Novo Nordisk, OncoMed Pharmaceuticals, Oncothyreon, Oncovir, Opexa Therapeutics, Oxford BioMedica, Pfizer, Prima BioMed, Principia, Progenics, Provectus Biopharmaceuticals, Regeneron, Sandoz, Sanofi, Santarus, Seattle Genetics, Sotio, Spectrum Pharmaceuticals, Takeda, TG Therapeutics, Transgene, UbiVac, UCB, Vaccinex, Vaccinogen, Vaxon Biotech, Vertex Pharmaceuticals, Vical, Vitae Pharmaceuticals, and XBiotech.
Key questions answered in the report include
- What will the market size and the growth rate be in 2020?
- What are the key factors driving the global immunotherapy drugs market?
- What are the key market trends impacting the growth of the global immunotherapy drugs market?
- What are the challenges to market growth for immunotherapy drugs?
- Who are the key vendors in the global immunotherapy drugs market?
- What are the market opportunities and threats faced by the vendors in the immunotherapy drugs market?
- Trending factors influencing the market shares of the Americas, APAC, and EMEA.
- What are the key outcomes of the five forces analysis of the global immunotherapy drugs market?
For more information or any query mail at [email protected]
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.

— The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Complete report on Psoriatic Arthritis - Pipeline Review, H2 2016 addition with 53 market data tables and 15 figures, spread across 231 pages is available at http://www.reportsnreports.com/reports/755895-psoriatic-arthritis-pipeline-review-h2-2016.html
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries,conferences,SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis
3SBio,AbbVie, AbGenomics International,Alteogen ,Amgen,Biocon ,Bionovis, Bristol-Myers Squibb Company, Celgene Corporation, Coherus BioSciences, Eli Lilly and Company, Forward Pharma A/S, Genor BioPharma Co Ltd, Innovent Biologics, Johnson & Johnson, Kadmon Corporation, KPI Therapeutics,Momenta Pharmaceuticals, Morphotek Mycenax Biotech, NeuClone Pty Ltd, Novo Nordisk A/S Oncobiologics, Pfizer Sandoz International
Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=755895(This is a premium report price at US$2000 for a single user PDF license).
• The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis
• The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects
• The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
For more information, please visit http://www.reportsnreports.com

DelveInsight’s, “Peripheral Lung Cancer -Pipeline Insights, 2016”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the 12 pipeline drugs that fall under the category of Peripheral Lung Cancer. Peripheral lung cancer usually begins in tissues that lie near the outer parts of the lungs, and may be diagnosed later in due course of time.
The report also provides the recent trends as these days’ companies are focusing on the Targeted Therapy for cancer majorly on the inner working of the lung cancer cells and process, which will control their growth and spread. Morphotek’s Farletuzumab is the only monoclonal antibody in Phase II competing against the other small molecules in development along with Solitomab of Amgen in Phase I.
Recent report of Delveinsight covers drugs that are being developed with novel approach to target or intervene along the pathways of tumorigenesis. Currently in pipeline, we can observe close competition between the Phase II drugs of Big Pharma such as Pfizer and Eisai along with mid tier companies such as Hanmi, Axelar and Morphotek. Boehringer is leading both in market as well as in pipeline with Afatinib in Phase III stage of development.
Scope:
• The new report, provides a Peripheral Lung Cancer Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
• Coverage of the Peripheral Lung Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Peripheral Lung Cancer and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.
Reasons to Buy:
• Complete Pipeline intelligence and complete understanding over therapeutics development for Peripheral Lung Cancer
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Peripheral Lung Cancer pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
For more information or any query mail at [email protected]

Amatuximab is a chimeric high-affinity monoclonal IgG1/k antibody targeting mesothelin that is being developed for treatment of mesothelin-expressing cancers. Considering the ongoing clinical development of amatuximab in these cancers, our objective was to characterize the biodistribution, and dosimetry of 111Indium (111In) radiolabelled amatuximab in mesothelin-expressing cancers. Between October 2011 and February 2013, six patients including four with malignant mesothelioma and two with pancreatic adenocarcinoma underwent Single Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) imaging following administration of 111In amatuximab. SPECT/CT images were obtained at 2-4 hours, 24-48 hours and 96-168 hours after radiotracer injection. In all patients, tumor to background ratios (TBR) consistently met or exceeded an uptake of 1.2 (range 1.2-62.0) which is considered the minimum TBR that can be visualized. TBRs were higher in tumors of patients with mesothelioma than pancreatic adenocarcinoma. 111In-amatuximab uptake was noted in both primary tumors and metastatic sites. The radiotracer dose was generally well-tolerated and demonstrated physiologic uptake in the heart, liver, kidneys and spleen. This is the first study to show tumor localization of an antimesothelin antibody in humans. Our results show that 111In-amatuximab was well tolerated with a favorable dosimetry profile. It localizes to mesothelin expressing cancers with a higher uptake in mesothelioma than pancreatic cancer.